NEW YORK, Sept. 11, 2017 /PRNewswire/ -- The global market for pain management will grow from nearly $36.1 billion in 2017 to $52.0 billion by 2022, with a compound annual growth rate (CAGR) of 7.6% for the period of 2017-2022.
Read the full report: https://www.reportlinker.com/p01080064
• The pharmaceutical segment will grow from $32.3 billion in 2017 to $47.6 billion by 2022, rising at a CAGR of 8.1%.
• The device segment is expected to increase from $3.7 billion in 2017 to nearly $4.4 billion by 2022 with a CAGR of 3.3%.
Chapter 1: Introduction
Study Goals and Objectives
This BCC Research report, The Global Market for Pain Management Drugs and Devices, provides an overview of products included in this market, and detailed analyses of markets and competitive environments. The study includes information about significant products, players, issues and trends, regulatory issues, and other information affecting the pain management industry.
Reasons for Doing This Study
This study will provide the reader with the knowledge to adequately view and assess pain management and the problems that the healthcare industry faces in this space. The study also provides insights into the market potential in both the pharmaceutical and device segments. This covers a wide variety of treatments and products that many people worldwide rely on; however, there are several areas where treatment is inadequate and underserved. The report is designed to provide the reader with a background of the pain management industry, current factors influencing growth and provide decision makers with the tools to make decisions regarding expanding or exiting from the pain management industry.
Scope of Report
This BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study will address acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.
The report identifies two general segments of pain management:
• Pharmaceuticals.
• Devices.
Within the pharmaceuticals segment several sub-segments are discussed in detail including:
• Narcotic pain management.
• Non-narcotic pain management.
• Antimigraine treatments.
• Anesthetics.
• Other drugs (including CNS therapies).
The device segment covers several product lines and specifically targets the largest product segments including:
• Electrotherapy stimulators.
• Spine stimulators.
• Other products (including electromagnetic therapies and other treatments).
Each market segment provides detailed information based on product categories, product use, forecasts and competitive analyses. Not covered in the report are drugs or devices that by treating the condition or disorder result in the relief of pain. These include treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other similar diseases. Treatments are only included for those that indicate a relief of pain symptoms associated with these conditions. A comparison of a treatment for the disease that naturally relieves the symptoms as compared to treatments for the relief of pain associated with the disease include:
• Enbrel1: Indicated for the treatment of moderate-to-severe rheumatoid arthritis.
• Celebrex2: Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.
The report is also evaluated in terms of application, discussing market trends and performance for the following areas:
• Surgical pain.
• Orthopedic/musculoskeletal pain.
• Migraine pain.
• Fibromyalgia pain.
• Cancer pain.
• Neuropathic pain.
• HIV/AIDS pain.
• Dental pain.
• General pain.
1 Pfizer Inc. product label
2 Pfizer Inc. product label
Methodology and Information Sources
The information for this BCC Research report was obtained through primary and secondary data collection methods. Primary methods included interviews with nearly 50 industry experts and participants, including industry executives, physicians, nurses, product managers and other professionals involved in the pain treatment industry. Secondary methods includes published literature in pain management, insurance and reimbursement databases, investment reports, company literature and various related journals. Market data for this report pertains to the global market and uses U.S. dollars at the manufacturers' level. The base year of the report is 2017, with historical data provided for 2014 through 2016, and forecast data provided through 2022. Historical, base year and forecast data are provided for each market segment of the report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, and current product growth, etc.
Geographic Breakdown
The markets for pain management drugs and devices are divided into four broad regions:
North America
• Canada.
• United States.
Europe, Middle East, Africa (EMEA)
• Egypt.
• France.
• Germany.
• Iran.
• Iraq.
• Israel.
• Italy.
• Poland.
• Russia.
• Saudi Arabia.
• Spain.
• Turkey.
• Ukraine.
• United Kingdom.
Asia-Pacific
• Australia.
• China.
• India.
• Indonesia.
• Japan.
• Malaysia.
• New Zealand.
• Philippines.
• South Korea.
• Singapore.
• Taiwan.
• Thailand.
• Vietnam.
Latin America
• Argentina.
• Brazil.
• Colombia.
• Mexico.
• Venezuela.
Read the full report: https://www.reportlinker.com/p01080064
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article